Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Revenue of Molecular Partners AG (MOLN)
Revenue in 2023 (TTM): $7.04 M
According to Molecular Partners AG's latest financial reports the company's current revenue (TTM) is $7.04 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Molecular Partners AG
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $7.04 M | $-40,806,000 | $-59,530,000 | $-61,984,000 | $-61,984,000 |
| 2022 | $189.56 M | $138.81 M | $120.85 M | $117.85 M | $117.85 M |
| 2021 | $9.33 M | $-46,388,000 | $-60,853,000 | $-63,783,000 | $-63,785,000 |
| 2020 | $9.34 M | $-46,731,000 | $-59,593,000 | $-62,775,000 | $-62,764,000 |
| 2019 | $20.38 M | $-23,115,000 | $-33,711,000 | $-36,271,000 | $-36,288,000 |
| 2018 | $10.36 M | $-5,247,000 | $-36,268,000 | $-37,036,000 | $-37,036,000 |
| 2017 | $20.02 M | $2.19 M | $-24,699,000 | $-25,430,000 | $-25,430,000 |
| 2016 | $23.04 M | $8.47 M | $-18,062,000 | $-18,612,000 | $-18,612,000 |
| 2015 | $29.12 M | $27.95 M | $-1,022,639 | $-148,823 | $-148,823 |
| 2014 | $26.63 M | $26.45 M | $-1,472,371 | $-2,282,756 | $-2,282,756 |
| 2013 | $32.42 M | $31.2 M | $7.93 M | $7.14 M | $7.14 M |